Zhang Y.,First Hospital of Liaoning Medical College |
Liang W.,Morphological Test Center |
Peng D.,General Hospital of Liaohe Oil Field |
Li C.,First Hospital of Liaoning Medical College |
Gao Z.,First Hospital of Liaoning Medical College
Chinese Journal of Cancer Biotherapy | Year: 2013
Objective: To explore the clinical significance of the expressions of XIAP(X-linked inhibitor of apoptosis protein) and caspase-3 in colorectal adenocarcinoma and adenoma. Methods: Sixty-seven cases with colorectal adenocar-cinoma, 30 cases of colorectal adenoma cases selected from the Department of Pathology, First Affiliated Hospital of Liaoning Medical College from 2010 to 2012 with surgical resection, and 30 cases of corresponding adjacent mucosa (the distance from the edge of the cancerous tissue 5 cm) were used as a control. Immunohistochemistry was used to detect the expressions of XIAP and caspase-3 proteins in colorectal adenocarcinoma and adenoma tissues; Western blotting was used to detect the expression of XIAP in the colorectal adenocarcinoma and adenoma tissues; The relationship between the expression of XIAP and the clinical pathology parameters of colorectal adenocarcinoma was analyzed. Results: The positive rate of XIAP expression in the colorectal adenoma group (71. 6%) was higher than that in colorectal adenocarcinoma (46. 7%), and its expression rate was increasing with the decrease of the tissue differentiation degree (x2 = 16.132, P < 0. 05); the positive rate of caspase-3 expression in the colorectal adenocarcinoma tissues (18. 0%) was lower than that in the colorectal adenoma group (43.3%), and its expression rate was decreased with the decrease of the pathological differentiation degree (P <0. 05). The expression of XIAP protein was in a negative correlation with that of caspase-3 (r = 0. 396, P < 0. 05). Conclusion: The XIAP protein might play a significant role in promoting the progress from colorectal adenoma to colorectal adenocarcinoma bv inhibiting caspase-3.
Liu Y.,China Medical University at Heping |
Liu Y.,First Hospital of Liaoning Medical College |
Xi H.,China Medical University at Heping |
Xi H.,Anthropology Institute |
And 2 more authors.
Journal of Voice | Year: 2012
Objectives/Hypothesis: Laryngeal edema is a common clinical condition. However, the underlying molecular mechanisms remain elusive. Aquaporins (AQPs) are small integral plasma membrane proteins that transport water across the plasma membrane. In this study, we explore the relationship between inflammatory laryngeal edema induced by compound 48/80 and the expression of AQPs. Study Design: Prospective, controlled, experimental animal study. Methods: Healthy adult male SD rats were injected with either sterile water, compound 48/80 (2 mg/kg), or compound 48/80 plus dexamethasone (3 mg/kg) via the tail vein. The larynxes were harvested 10, 30 minutes, and 1 hour after the injection for the measurement of sublaryngeal water content and histological and molecular evaluations. Results: Ten and 30 minutes after the compound 48/80 injection compared with the sterile water injection control groups, the water content in subglottic larynx increased significantly and the tissues were markedly swollen accompanied with inflammatory cell infiltration. AQP1 and AQP5 mRNA decreased significantly. One hour after the compound 48/80 injection, the edema was diminished, but the inflammatory cell infiltration remained. AQP1 was elevated but AQP5 was still lower than controls. Dexamethasone did not significantly reduce laryngeal edema, but significantly reduced inflammatory cells infiltration induced by compound 48/80 injection. Dexamethasone increased the AQP5 level but not AQP1. Conclusions: AQP1 and AQP5 might play key roles in inflammatory subglottic edema caused by compound 48/80 in rats. AQP1 and AQP5 might be useful molecular targets of clinical treatment of inflammatory laryngeal edema. © 2012 The Voice Foundation.
Lei Z.,China Medical University at Heping |
Lei Z.,First Hospital of Liaoning Medical College |
Ma H.,First Hospital of Liaoning Medical College |
Xu N.,First Hospital of Liaoning Medical College |
Xi H.,Anthropology Institute
European Journal of Radiology | Year: 2011
Objective: Investigate the benefit of functional multi-slice spiral computed tomography (f-MSCT) perfusion imaging in the non-invasive assessment of targeted anti-angiogenesis therapy on an implanted rabbit VX2 breast tumor model. Method: 69 female pure New Zealand white rabbits were randomly assigned to one of the 4 groups and received treatment accordingly: control (saline), Endostar, neoadjuvant chemotherapy (Cyclophosphamide, Epirubicin and 5-Fluorouracil, CEF), combination therapy (Endostar and CEF). After 2 weeks of treatment, f-MSCT perfusion scannings were performed for all rabbits and information about blood flow (BF), blood volume (BV), mean transit time (MTT) and surface permeability (SP) was collected. After perfusion imaging, tumor tissues were sampled for immunohistochemistry and the Western blot test of VEGF protein expression. Results: (1) The VEGF expression level, measured by immunohistochemistry and Western blot, decreased by treatment group (control > Endostar > CEF > combination therapy). The same was true for the mean BF, BV, MTT and PS, which decreased from the control group to the combination therapy group gradually. The mean MTT level increased in reverse order from the control to the combination therapy group. The difference between any 2 groups on these measures was statistically significant (P < 0.05). (2) There was moderate positive correlation between VEGF expression and BE, BV, or PS level (P < 0.05) and a negative correlation between VEGF expression and MTT level for all 4 groups (P < 0.05). Conclusion: Therefore, f-MSCT can be used as a non-invasive approach to evaluate the effect of anti-angiogenic therapy for implanted rabbit VX2 breast tumors. © 2011 Elsevier Ireland Ltd. All rights reserved.
Zhang J.,General Hospital of Shenyang Military Command |
Li Y.,General Hospital of Shenyang Military Command |
Tao G.-Z.,First Hospital of Liaoning Medical College |
Chen Y.-D.,General Hospital of Peoples Liberation Army |
And 12 more authors.
Chinese Medical Journal | Year: 2015
Background: Current randomized trials have demonstrated the effects of short-term rosuvastatin therapy in preventing contrast-induced acute kidney injury (CIAKI). However, the consistency of these effects on patients administered different volumes of contrast media is unknown. Methods: In the TRACK-D trial, 2998 patients with type 2 diabetes and concomitant chronic kidney disease (CKD) who underwent coronary/peripheral arterial angiography with or without percutaneous intervention were randomized to short-term (2 days before and 3 days after procedure) rosuvastatin therapy or standard-of-care. This prespecified analysis compared the effects of rosuvastatin versus standard therapy in patients exposed to (moderate contrast volume [MCV], 200–300 ml, n = 712) or (high contrast volume [HCV], ≥300 ml, n = 220). The primary outcome was the incidence of CIAKI. The secondary outcome was a composite of death, dialysis/hemofiltration or worsened heart failure at 30 days. Results: Rosuvastatin treatment was associated with a significant reduction in CIAKI compared with the controls (2.1% vs. 4.4%, P = 0.050) in the overall cohort and in patients with MCV (1.7% vs. 4.5%, P = 0.029), whereas no benefit was observed in patients with HCV (3.4% vs. 3.9%, P = 0.834). The incidence of secondary outcomes was significantly lower in the rosuvastatin group compared with control group (2.7% vs. 5.3%, P = 0.049) in the overall cohort, but it was similar between the patients with MCV (2.0% vs. 4.2%, P = 0.081) or HCV (5.1% vs. 8.8%, P = 0.273). Conclusions: Periprocedural short-term rosuvastatin treatment is effective in reducing CIAKI and adverse clinical events for patients with diabetes and CKD after their exposure to a moderate volume of contrast medium. © 2015, Chinese Medical Association. All Rights Reserved.
Yang Y.,Peking Union Medical College |
Zhang Z.,First Hospital of Liaoning Medical College |
Wang R.,Peking Union Medical College |
Ma W.,Peking Union Medical College |
And 2 more authors.
Molecular and Cellular Biochemistry | Year: 2013
SMC1A is a member of cohesin complex which has essential functions in cell cycle progression and DNA repair. Therefore, we choose SMC1A as a target gene therapy of glioblastoma. It is well known that glioblastoma has very low survival rate because of ineffectiveness of conventional treatments. This study was designed to explore the possibilities of small interfering RNA (siRNA)- mediated SMC1A silencing as alternative method of treatment. We found that the lentivirus-mediated RNAi system efficiently decreased the expression level of SMC1A. Inhibiting SMC1A expression efficiently (P<0.001) resulted in inhibiting the proliferation and colony formation of U251 and U87MG cells. Moreover, we found that SMC1A silencing led to S cell-cycle arresting. Collectively, these results demonstrated the possibility of siRNA-mediated silencing of SMC1A as a therapeutic tool for the treatment of glioblastoma. © 2013 Springer Science+Business Media New York.